Comment: Adjuvant ipilimumab in high-risk melanoma - Listen - 2014

2014 ASCO Annual Meeting

Comment: Adjuvant ipilimumab in high-risk melanoma

Listen now

Description

At ASCO 2014, Dr O'Day provides ecancertv with his expert opinion on the final analysis on the impact of ipilimumab on relapse-free survival from a randomised phase III study, EORTC 18071, which indicates that adjuvant (post-surgery) therapy with ipilimumab for patients with high-risk stage III melanoma decreases the relative risk of cancer recurrence by roughly 25 percent compared to placebo.

More Episodes

See all »

Comment: PD-1 targeting MK-3475 gives long-term responses in melanoma

At ASCO 2014, Dr O'Day provides ecancertv with his expert opinion on the findings from a large phase I study of 411 patients with advanced melanoma which showed that the PD-1 targeting antibody MK-3475 yields long-term responses in a high percentage of patients.

Published 07/15/14

2014 ASCO Annual Meeting

Published 07/15/14

ASCO 2014 roundup

ecancer's Prof McVie provides a roundup of the main points of discussion from ASCO 2014.

Published 07/11/14